RE:Pfizer partners with startup Flagship valued at US$7 BillionBig Pharma is prepared to spend Billion$$ and is having to reach further upstream in the R&D process in an effort to gain new assets to help stave off the looming patent cliff that they face and replenish their dwindling product portfolios.
As described earlier, M&A valuations for late-state clinical stage companies developing biologicals continue to be acquired at premium pricing, and have become very competitive assets to acquire, particularly in immuno-ocology products in the treatment of multiple cancers.
ONCY's pelareorep is demonstrating effectiveness in multiple cancers including breast and gastrointestinal cancers like pancreatic, anal, and colorectal cancer.